Financial Performance - The company's operating revenue for Q1 2023 was CNY 87,762,301.30, representing a year-on-year increase of 16.18%[5]. - Net profit attributable to shareholders decreased by 38.40% year-on-year, amounting to CNY 14,307,104.28[5][9]. - The net profit after deducting non-recurring gains and losses fell by 47.96%, totaling CNY 7,302,325.16[5][9]. - The net profit for Q1 2023 was CNY 13,529,876.56, a decrease of 38.5% compared to CNY 22,013,486.90 in Q1 2022[20]. - Operating profit for Q1 2023 was CNY 11,084,400.27, down 43.4% from CNY 19,512,167.40 in the same period last year[20]. - The total comprehensive income for Q1 2023 was CNY 13,529,876.56, compared to CNY 21,533,439.04 in Q1 2022[21]. - Basic and diluted earnings per share were both CNY 0.12, reflecting a decrease of 37.25% year-on-year[6][9]. - Basic and diluted earnings per share for Q1 2023 were both CNY 0.12, down from CNY 0.19 in the same quarter last year[21]. Cash Flow - The net cash flow from operating activities was negative at CNY -5,286,511.48, a decline of 108.22% compared to the previous year[6][9]. - Cash flow from operating activities turned negative at CNY -5,286,511.48, compared to a positive CNY 64,335,059.13 in Q1 2022[24]. - The company reported a net cash outflow from investing activities of CNY -108,285,178.74, an improvement from CNY -187,471,146.88 in Q1 2022[24]. - The total cash inflow from investment activities was CNY 161,357,266.04, a decrease of 50.0% compared to CNY 323,026,382.45 in Q1 2022[34]. - The net cash flow from investment activities was -CNY 111,127,175.72, an improvement from -CNY 189,490,113.90 in Q1 2022[34]. - Cash and cash equivalents at the end of Q1 2023 were CNY 361,033,982.93, down from CNY 529,569,351.18 at the end of Q1 2022[34]. - The cash outflow for purchasing goods and services increased to CNY 76,920,055.38, up 105.0% from CNY 37,475,015.22 in Q1 2022[32]. - The company did not report any cash inflow from financing activities in Q1 2023[34]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,592,109,549.99, a decrease of 1.16% from the end of the previous year[6]. - Total assets as of March 31, 2023, amounted to RMB 1,592,109,549.99, a slight decrease from RMB 1,610,828,359.79 at the end of 2022[15]. - Total liabilities decreased to RMB 150,553,704.96 from RMB 185,767,562.26, indicating a reduction of 19%[16]. - The company's total liabilities decreased to CNY 199,235,766.86 in Q1 2023 from CNY 234,618,597.19 in Q4 2022, a reduction of approximately 15.1%[28]. - Shareholders' equity increased to RMB 1,441,555,845.03 from RMB 1,425,060,797.53, showing a growth of 1.2%[16]. - The company's total equity increased to CNY 1,461,999,276.93 in Q1 2023 from CNY 1,444,628,761.79 in Q4 2022, showing a growth of 1.2%[28]. Research and Development - Research and development expenses totaled CNY 7,517,071.87, which is 8.57% of operating revenue, an increase of 0.46 percentage points year-on-year[6]. - Research and development expenses increased to CNY 7,517,071.87, up 22.8% from CNY 6,121,712.21 in the previous year[20]. - Research and development expenses increased to CNY 6,578,632.54 in Q1 2023, up from CNY 5,491,702.14 in Q1 2022, indicating a growth of 19.8%[30]. Inventory and Accounts Payable - Inventory levels rose to RMB 115,581,174.69, up from RMB 81,490,915.63, marking an increase of 42%[14]. - The company reported a decrease in accounts payable to RMB 86,224,694.99 from RMB 107,335,303.41, a decline of 19.7%[15]. - The company's inventory increased to CNY 110,586,346.86 in Q1 2023 from CNY 78,443,729.20 in Q1 2022, reflecting a growth of 41.0%[27]. Market Strategy - The company is focused on expanding its market presence and developing new technologies, although specific details were not disclosed in the report[13].

Financial Performance - The company's operating revenue for 2022 was CNY 433.42 million, an increase of 23.44% compared to CNY 351.11 million in 2021[22]. - Net profit attributable to shareholders decreased by 49.94% to CNY 64.37 million from CNY 128.58 million in 2021[22]. - The net cash flow from operating activities increased by 70.78% to CNY 176.40 million compared to CNY 103.29 million in 2021[22]. - Basic earnings per share dropped by 49.53% to CNY 0.54 from CNY 1.07 in 2021[23]. - The total assets of the company increased by 11.21% to CNY 1.61 billion from CNY 1.45 billion in 2021[22]. - The company reported a significant increase in sales expenses due to intensified market expansion efforts for new products and services[24]. - The gross margin for human nutrition products was 46.47%, a decrease of 3.71 percentage points compared to the previous year[103]. - The company’s ARA product revenue was CNY 255,584,220.82, with a gross margin of 49.34%, down by 0.48 percentage points[104]. - Domestic market revenue growth was limited to 2.56% due to inventory destocking in the dairy industry[105]. - The international market revenue increased by 36.42%, benefiting from higher market share with major clients like Nestlé[105]. Research and Development - The company is focused on expanding its market presence and developing new products and technologies[12]. - Research and development expenses accounted for 7.45% of operating revenue, down from 8.81% in 2021[23]. - The company has developed over 15 new products using synthetic biology technology and established an industrial strain library in 2022[42]. - The company has formed strategic partnerships with multiple universities and research institutions to enhance its R&D ecosystem[41]. - The company achieved a total R&D investment of ¥32,296,449.13, representing a 4.36% increase from the previous year's ¥30,947,095.88[78]. - The company has developed a series of products using lipid nano co-delivery technology, showing good moisturizing and repair effects[70]. - The company has developed over 31 enzymes related to the synthesis pathways of HMOs and polyunsaturated fatty acids, achieving structural analysis or prediction[67]. - The company has established a comprehensive technology system for the efficient construction of industrial strains, achieving international advanced levels in strain rearrangement technology[82]. Market Expansion and Strategy - The company plans to enhance its product line by accelerating the development of new products, including HMOs and α-arbutin[143]. - The company aims to maintain its leadership position in the domestic ARA market while increasing its international market share[143]. - The company is actively developing new products and expanding into animal nutrition and personal care sectors, leveraging its expertise in human nutrition[93]. - The company aims to become a leading brand in the global ARA market and a major supplier in the algae oil DHA market, focusing on international development strategies in Australia and Southeast Asia[144]. - The company plans to explore international markets following the expiration of DSM's ARA patents in June 2023, targeting Europe, North America, and Southeast Asia for expansion[147]. Corporate Governance and Investor Relations - The company emphasizes that forward-looking statements do not constitute a commitment to investors, highlighting investment risks[6]. - The company is committed to ensuring the accuracy and completeness of its financial reports[5]. - The company has implemented a stock incentive plan to motivate and retain key personnel[164]. - The company plans to enhance its capital brand and value communication with investors in the future[161]. - The company has not faced significant issues regarding independence from its controlling shareholders[161]. - The company will maintain strict information disclosure obligations and improve investor relations management to ensure transparency and trust[160]. Operational Risks and Compliance - The company has detailed various operational risks and corresponding mitigation measures in the report[4]. - The company has no non-operational fund occupation by controlling shareholders or related parties[7]. - The company has no violations of decision-making procedures regarding external guarantees[8]. - The company faces risks related to food safety and product quality control, which are critical in the infant formula sector, and any failure in these areas could lead to significant negative impacts[93]. - The company is exposed to risks from fluctuations in energy and raw material prices, which could affect production costs and profitability[94]. Awards and Recognition - The company has received multiple awards, including the National Science and Technology Progress Award, and has participated in the formulation of national standards[60]. - The company has received multiple awards for its technological advancements, including a first prize for technological progress from the China Light Industry Federation[70]. Future Outlook - Future guidance indicates a cautious outlook, with expectations of gradual recovery in user engagement metrics[167]. - The company plans to implement a new marketing strategy aimed at increasing brand awareness, with a budget allocation of $50 million[168]. - The company is exploring partnerships with key industry players to enhance distribution channels and drive growth[168].

关于上海证券交易所《关于嘉必优生物技术 （武汉）股份有限公司 2022 年业绩快报 更正暨资产减值风险、补充确认关联交易等 有关事项的问询函》回复的核查意见 大信备字[2023]第 2-00012 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants LLP. Room2206 22/F,Xueyuan International Tower No.1 ZhichunRoad,Haidian Dist. Beijing,China,100083 电话 Telephone： +86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 关于上海证券交易所《关于嘉必优生物技术（武汉）股份有限 公司 2022 年业绩快报更正暨资产减值风险、补充确认关联交 易等有关事项的问询函》回复的核查意见 大信备 ...

编号：2022-06 投资者关系 活动类别 特定对象调研 分析师会议 □媒体采访 □业绩说明会 □新闻发布会 路演活动 现场参观 其他 电话会议 证券代码： 688089 证券简称： 嘉必优 嘉必优生物技术（武汉）股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |----------------|-------|---------------------------|--------| | | | | | | 参与单位名称及 | 序号 | 公司 | 姓名 | | | | 4 月 30 日 10:00-11:00 | | | 人员姓名 | 1 | 开源证券 | 方勇 | | | 2 | 浙商 | 韩佳伟 | | | 3 | 长城财富 | 缴文超 | | | 4 | 财通基金 | 姜春曦 | | | 5 | 德邦 | 刘敏 | | | 6 | 恒越 | 陈凯茜 | | | 7 | 华泰柏瑞 | 王欣然 | | | 8 | 中邮 | 綦征 | | | 9 | 招银理财 | 杨鈜毅 | | | 10 | 太平 | 肖婵 | | | 11 | 太平 | 项韬 | | | 12 | ...

编号：2022-07 投资者关系 特定对象调研 分析师会议 活动类别 □媒体采访 □业绩说明会 □新闻发布会 路演活动 现场参观 其他 电话会议 证券代码： 688089 证券简称： 嘉必优 嘉必优生物技术（武汉）股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------------|-----------------------------------| | | | | | 参与单位名称及 | 机构名称 | 参会人员 | | 人员姓名 | 5 | 月 11 日 15:00-15:50 | | | UBS | Mandy Liu | | | New Silk Road Investment | Xin Feng | | | Manulife AM | Wenlin Li | | | Sage Partner | Joey Zou | | | WT capital | Ray Fang | | | Ironbirch | Davey C. Leu | | | 5 | 月 13 日 14:00-15:30 | | | 泰 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥102,096,355.32, representing a year-on-year increase of 17.62%[5] - The net profit attributable to shareholders for the same period was ¥27,841,760.00, showing a decline of 16.60% compared to the previous year[5] - Total operating revenue for the first three quarters of 2022 reached ¥273,244,476.30, an increase of 9.3% compared to ¥249,908,128.65 in the same period of 2021[22] - Net profit for the first three quarters of 2022 was ¥75,304,227.69, a decrease of 27.8% from ¥104,179,165.99 in the same period of 2021[23] - Basic earnings per share for the third quarter of 2022 were ¥0.65, down from ¥0.84 in the same quarter of 2021[24] - The total profit for the first three quarters of 2022 was ¥86,642,442.11, down 10.7% from ¥97,107,838.54 in the same period of 2021[32] Research and Development - The R&D expenses for Q3 2022 totaled ¥11,663,668.37, which is an increase of 99.55% year-on-year, reflecting the company's commitment to expanding its R&D efforts[11] - The proportion of R&D expenses to operating revenue increased to 11.42%, up by 4.69 percentage points from the previous year[6] - Research and development expenses for the first three quarters of 2022 were ¥26,333,080.29, compared to ¥17,352,441.12 in the same period of 2021, reflecting a significant investment in innovation[22] - Research and development expenses increased to ¥23,355,921.81, up 53.0% from ¥15,279,592.55 in the previous year[32] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥83,502,609.85, marking an increase of 56.45% compared to the same period last year[6] - The net cash flow from operating activities for the first three quarters of 2022 was CNY 83,502,609.85, an increase of 56.4% compared to CNY 53,374,936.52 in the same period of 2021[25] - The company's cash and cash equivalents decreased to CNY 386,592,981.73 from CNY 664,467,646.87, representing a decline of about 42%[17] - The company's cash and cash equivalents at the end of the period were CNY 382,905,701.10, slightly up from CNY 364,748,739.86 at the end of the previous year[26] - The cash flow from financing activities resulted in a net outflow of -CNY 6,704,513.99, an improvement from -CNY 39,600,000.00 in the same period last year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,541,758,615.76, representing a growth of 6.44% from the end of the previous year[6] - The equity attributable to shareholders at the end of the reporting period was ¥1,428,729,447.17, an increase of 3.45% compared to the previous year[6] - Total liabilities as of the end of the third quarter of 2022 amounted to ¥111,224,600.46, compared to ¥66,677,032.94 at the end of the same period in 2021[20] - The total liabilities increased to CNY 165,419,076.55 from CNY 119,249,041.44, representing a rise of 38.7%[30] - The company's total equity as of September 30, 2022, was CNY 1,425,025,639.81, an increase from CNY 1,379,574,266.50 at the end of 2021, showing a growth of 3.3%[30] Shareholder Information - The company reported a total of 5,570 common shareholders at the end of the reporting period[13] - The company reported a total of 53,100,000 shares held by Wuhan Xiwang Biological Engineering Co., accounting for 44.25% of total shares[14] Investment Activities - Total cash inflow from investment activities was CNY 593,707,456.91, up from CNY 297,485,123.75 in the previous year, indicating a significant increase of 99.7%[26] - The net cash flow from investment activities was -CNY 357,604,092.53, an improvement from -CNY 493,450,082.63 in the same period last year[26] - The company reported a net cash outflow from investing activities of ¥363,550,227.99, an improvement from a net outflow of ¥497,072,258.59 in the previous year[36] Operational Costs - Total operating costs for the first three quarters of 2022 were ¥210,886,748.75, up 31.1% from ¥160,807,974.69 in the previous year[22] - The company reported a total of CNY 147,348,154.50 in cash paid for goods and services, which is an increase of 44.8% compared to CNY 101,668,089.28 in the previous year[25]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 171,148,120.98, representing a 4.93% increase compared to CNY 163,108,902.46 in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 25.96% to CNY 50,023,996.90 from CNY 67,566,742.60 year-on-year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 35,892,316.09, down 23.41% from CNY 46,860,881.53 in the previous year[19]. - Basic earnings per share decreased by 25.00% to CNY 0.42 compared to the same period last year[20]. - Diluted earnings per share also decreased by 25.00% to CNY 0.42 compared to the same period last year[20]. - The total profit for the first half of 2022 was CNY 56,764,023.80, a decrease of 30.6% compared to CNY 81,710,377.91 in the first half of 2021[174]. - The company's net profit for the first half of 2022 was CNY 41,155,064.12, compared to CNY 60,656,131.82 in the same period of 2021, reflecting a decrease of 32.1%[173]. Cash Flow and Investments - The net cash flow from operating activities increased significantly by 122.69% to CNY 90,455,918.15, compared to CNY 40,618,997.36 in the same period last year[19]. - The company's cash and cash equivalents decreased by 31.34% to CNY 456,242,956.66, primarily due to unexpired bank financial products[75]. - The total cash inflow from sales of goods and services was ¥200,937,480.28, an increase from ¥142,596,615.14 in the first half of 2021, representing a growth of about 40.7%[180]. - The cash inflow from investment activities totaled ¥295,435,444.60, down from ¥424,202,066.91 in the previous year, reflecting a decrease of about 30.3%[185]. - The net cash flow from investment activities was -¥354,873,504.91, compared to -¥260,665,496.35 in the same period of 2021, indicating a worsening of 36.0%[185]. Research and Development - R&D investment as a percentage of operating revenue increased by 1.51 percentage points to 8.57%[20]. - The total R&D investment for the first half of 2022 was approximately ¥14.67 million, representing a 27.48% increase from ¥11.51 million in the same period last year[42]. - The company has obtained 9 new patents in the first half of 2022, bringing the total number of patents to 86[41]. - The company has developed high-value products such as 2'-FL, 3'-SL, astaxanthin, and EPA, with 2'-FL achieving 96% purity and currently in regulatory approval phase[36]. - The company is establishing an intelligent R&D platform to integrate synthetic biology research, smart fermentation testing, and high-throughput detection, reducing the time from strain construction to industrialization[35]. Market and Sales Strategy - International sales accounted for nearly 50% of total revenue in the first half of 2022, with ongoing negotiations with multiple international clients[58]. - The company has formed long-term partnerships with major clients such as Nestlé and Danone, enhancing its brand reputation and customer resource base[56]. - The company is actively expanding its international supply chain and distribution channels, covering over 30 countries and regions[56]. - The domestic sales model primarily relies on direct sales, while the international market uses a distributor-based approach, facilitating rapid market expansion[29]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[119]. Environmental Compliance - The company has implemented a comprehensive waste gas treatment system, including five water washing towers and a UV purification system, to ensure compliance with emission standards[96]. - The company has established emergency response plans for environmental incidents at both the GeDian and Jiangxia branches, conducting regular drills and filing with local environmental authorities[100]. - The company has not faced any administrative penalties for environmental issues during the reporting period[106]. - The company has committed to sustainability initiatives, aiming to reduce carbon emissions by 50% by 2025[129]. - The company replaced refrigerants in cooling facilities with a new fluorine-free refrigerant, achieving a 10% increase in cooling capacity and an average energy efficiency improvement of over 20%[107]. Shareholder and Financial Management - The company plans to maintain a dividend payout ratio of 30% to ensure shareholder returns while reinvesting in growth initiatives[119]. - The company has committed to a stable cash dividend policy to ensure consistent returns for investors, with plans to improve the profit distribution system[117]. - The company will comply with relevant laws and regulations regarding share reduction, including trading methods such as centralized bidding and block trading[114]. - The company has pledged to take corrective actions if it fails to meet its commitments regarding immediate return dilution, including public apologies and alternative commitments[117]. - The company has extended the lock-up period for its restricted shares by six months following the expiration date[134].

Financial Performance - The company's operating revenue for Q1 2022 was ¥75,542,426.37, representing a decrease of 4.17% compared to the same period last year[5] - The net profit attributable to shareholders was ¥23,224,988.14, down 31.20% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥14,031,578.96, a decline of 38.84% compared to the previous year[5] - Basic earnings per share were ¥0.19, reflecting a decrease of 32.14% year-on-year[6] - Net profit for Q1 2022 was ¥22,013,486.90, down 36.8% from ¥34,920,460.94 in Q1 2021[20] - Operating profit decreased to ¥19,512,167.40, a decline of 43.0% compared to ¥34,263,660.01 in Q1 2021[19] - The net profit for Q1 2022 was CNY 26,050,579.71, down from CNY 36,339,817.81 in Q1 2021, indicating a decline of 28.5%[27] - The overall comprehensive income for Q1 2022 was ¥22,707,014.78, consistent with the net profit reported[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,470,211,469.37, an increase of 1.50% from the end of the previous year[6] - The total number of common shareholders at the end of the reporting period was 5,670[10] - The company's cash and cash equivalents decreased to RMB 537,873,200.84 from RMB 664,467,646.87, representing a decline of about 19.0%[14] - The total current assets were reported at RMB 914,550,554.92, down from RMB 994,851,368.32, indicating a decrease of approximately 8.1%[14] - The company's long-term equity investments increased to RMB 40,264,899.30 from RMB 19,916,010.74, showing a significant growth of about 102.0%[14] - The total non-current assets rose to RMB 555,660,914.45 from RMB 453,639,525.42, marking an increase of approximately 22.5%[15] - The total liabilities decreased to RMB 55,897,974.91 from RMB 59,954,131.55, reflecting a reduction of about 6.8%[15] - Total liabilities decreased to ¥62,510,769.55 from ¥66,677,032.94 year-over-year[19] Cash Flow - The net cash flow from operating activities was ¥64,335,059.13, with significant improvement in receivables collection[9] - Cash flow from operating activities was ¥64,335,059.13, a significant improvement from a negative cash flow of -¥9,239,874.45 in Q1 2021[21] - Operating cash flow for Q1 2022 was ¥68,211,951.27, a significant improvement from a net cash outflow of ¥6,919,018.15 in Q1 2021[30] - Total cash inflow from operating activities was ¥143,336,265.90, compared to ¥67,946,369.30 in the same period last year, representing an increase of 110.5%[29] - The company reported a net cash outflow from investing activities of ¥189,490,113.90 in Q1 2022, an improvement from a larger outflow of ¥556,503,779.29 in Q1 2021[30] - The net cash flow from investment activities was -CNY 187,471,146.88, compared to -CNY 556,515,753.28 in the previous period[22] Research and Development - Research and development expenses totaled ¥6,121,712.21, accounting for 8.10% of operating revenue, an increase of 0.93 percentage points[6] - Research and development expenses for Q1 2022 were ¥6,121,712.21, slightly down from ¥5,657,883.23 in Q1 2021[19] - Research and development expenses for Q1 2022 were CNY 5,491,702.14, compared to CNY 4,924,930.92 in Q1 2021, reflecting an increase of 11.5%[27] Shareholder Equity - Total equity attributable to shareholders increased to ¥1,406,162,330.85 from ¥1,381,023,990.59 in the previous year[19] - The total equity increased to CNY 1,404,674,681.28 from CNY 1,379,574,266.50, showing a growth of 1.8%[27] Inventory and Other Assets - The company's accounts receivable decreased to RMB 122,112,077.98 from RMB 151,078,051.73, a decline of approximately 19.2%[14] - The inventory increased slightly to RMB 75,259,339.09 from RMB 74,855,595.02, indicating a marginal growth of about 0.5%[14] - The company reported a significant increase in other non-current assets to RMB 106,723,838.63 from RMB 74,891,804.01, representing a growth of approximately 42.5%[15] - The company's inventory as of March 31, 2022, was CNY 72,588,888.45, slightly up from CNY 72,413,944.54 at the end of 2021[24] Financial Management - The company's short-term borrowings and other financial liabilities were not disclosed in the report, indicating a focus on maintaining liquidity and managing debt levels[15] - The company did not report any cash inflow from financing activities in Q1 2022, indicating a focus on internal funding[30] - The company has not applied new accounting standards for the current year, maintaining consistency in financial reporting[31]

Financial Performance - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2021 was CNY 351,109,348.43, representing an increase of 8.55% compared to 2020[20]. - The net profit attributable to shareholders of the listed company decreased by 1.54% to CNY 128,578,881.86 in 2021[20]. - The net cash flow from operating activities decreased by 29.20% to CNY 103,291,182.60 compared to the previous year[20]. - The basic earnings per share for 2021 was CNY 1.07, a decrease of 1.83% from 2020[21]. - The total assets at the end of 2021 were CNY 1,448,490,893.74, reflecting a 4.75% increase from the end of 2020[20]. - The company's net assets attributable to shareholders increased by 4.79% to CNY 1,381,023,990.59 at the end of 2021[20]. - The company reported a significant increase in revenue, achieving a total of 8,207 million RMB, with a net profit of 3,094.72 million RMB, indicating a significant increase compared to the previous period[91]. - The company reported a total revenue of 4,471,643 million, reflecting a significant growth of 873.80% compared to the previous year[172]. Research and Development - Research and development expenses accounted for 8.81% of operating revenue, an increase of 2.51 percentage points from 2020[21]. - The company’s R&D investment exceeded CNY 30 million in 2021, focusing on synthetic biology technology and collaborations with research institutions[36]. - Total R&D investment reached ¥30,947,095.88, a significant increase of 51.82% compared to ¥20,384,052.34 in the previous year, with R&D investment accounting for 8.81% of operating revenue[85]. - The company reported a significant increase in R&D activities, with a focus on innovative food ingredients and health-related products[81]. - The company has filed for numerous patents, enhancing its core technology capabilities and reducing product costs[78]. - The company aims to integrate existing technologies to continuously innovate in product development and application solutions[76]. Market Expansion and Strategy - The company plans to continue focusing on R&D and market expansion strategies to enhance future performance[22]. - The company is expanding its production capacity with ongoing projects in microencapsulation and microbial oil refining, enhancing operational efficiency[36]. - The company is focusing on international market expansion, particularly in Australia and Southeast Asia, to capture a larger share of the global ARA and DHA markets[155]. - The company aims to achieve over 100 million in sales for its Omega-3 fatty acid product line in 2022, leveraging diverse strains and enhancing process technology to reduce costs[157]. - The company is exploring market expansion strategies, aiming to penetrate new geographical regions and increase market share[172]. Product Development - The company established a new business unit for animal nutrition and launched 8 new feed or feed additive products during the reporting period[34]. - New product developments include OPO and fucoidan lactose, which have completed pilot studies and are moving towards industrialization[77]. - The company is expanding its market presence through the development of new products, including a refined microbial oil and a new type of polyunsaturated fatty acid oil[81]. - The company is focusing on expanding its product offerings in the baking sector with new formulations that include DHA microcapsules[81]. - The company introduced a new subscription model, which is anticipated to increase recurring revenue by 20% over the next year[184]. Governance and Compliance - The company has received a standard unqualified audit report from Da Xin Accounting Firm[5]. - The company’s financial report is guaranteed to be true, accurate, and complete by its management team[6]. - The company has no significant differences in governance compared to regulations set by the China Securities Regulatory Commission[164]. - The company’s governance structure remains compliant with relevant laws and regulations, ensuring no major conflicts of interest with controlling shareholders[165]. - The company held a total of 8 board meetings during the year, with 3 conducted via communication methods[192]. Industry Trends and Risks - The biotechnology industry is recognized as a strategic emerging industry in China, with government support for biotechnological advancements and sustainable practices[45]. - The nutrition and health industry is rapidly growing in China, driven by increasing consumer health awareness and an aging population, positioning China as a major player in the global nutrition market[46]. - The company faces risks related to food safety and product quality control, which are critical in the infant formula sector[106]. - The company is exposed to raw material price volatility, which could negatively impact production costs and profitability[108]. - The company is navigating risks from intensified market competition and potential adverse changes in downstream industries[109]. Customer and Supplier Relationships - The company’s top five customers accounted for 72.38% of total sales, with no sales to related parties[127]. - The top five suppliers contributed to 43.78% of total purchases, with no purchases from related parties[128]. - Total procurement amount from top 5 suppliers reached 2,053.45 million RMB, accounting for 43.78% of annual procurement[130]. - The company has formed long-term stable partnerships with renowned infant formula companies such as Nestlé and Danone, with some collaborations lasting over 10 years[103]. Sustainability and Innovation - The company is committed to sustainability by developing methods for producing food-grade sialic acid and other health-oriented ingredients[81]. - The company aims to improve resource and energy utilization efficiency while promoting sustainable industry development[88]. - The company is focusing on sustainability initiatives, aiming to reduce carbon emissions by 30% by 2025[182]. - The company is enhancing its smart manufacturing capabilities to achieve a green production model, incorporating automation and digitalization into its production processes[155].

Financial Performance - The company's operating revenue for Q3 2021 was ¥86,799,226.19, representing a year-over-year increase of 1.76%[5] - The net profit attributable to shareholders decreased by 14.18% to ¥33,381,698.78 for the same period[5] - The net profit after deducting non-recurring gains and losses was ¥21,801,554.04, down 14.51% year-over-year[5] - Net profit for the third quarter of 2021 was ¥104,179,165.99, down from ¥113,843,435.64 in the same quarter of 2020, reflecting a decrease of approximately 8.8%[23] - Earnings per share for the third quarter of 2021 were ¥0.84, compared to ¥0.92 in the same quarter of 2020, showing a decline of about 8.7%[24] - The company reported a total comprehensive income of ¥104,007,803.01 for the third quarter of 2021, down from ¥113,595,784.77 in the same quarter of 2020, indicating a decrease of approximately 8.5%[24] Research and Development - Research and development expenses totaled ¥5,844,964.91, an increase of 55.01% compared to the previous year[6] - R&D expenses accounted for 6.73% of operating revenue, up 2.31 percentage points from the previous year[6] - The company plans to continue increasing investment in new business R&D and expanding its R&D team size[10] - Research and development expenses for the third quarter of 2021 were ¥17,352,441.12, up from ¥11,773,569.80 in the same period of 2020, representing an increase of about 47.8%[22] Cash Flow and Liquidity - Cash flow from operating activities showed a significant decline of 53.73% to ¥53,374,936.52 year-to-date[6] - Operating cash inflow for the first three quarters of 2021 was CNY 267,521,499.22, a decrease of 16.1% compared to CNY 318,864,151.12 in the same period of 2020[26] - The company reported a net cash flow from operating activities of CNY 53,374,936.52, significantly lower than CNY 115,354,810.57 in Q3 2020, indicating a decline of 53.7%[27] - Cash and cash equivalents were reported at ¥367,239,854.04, down from ¥847,316,269.30 in December 2020, indicating a significant reduction of about 56.6%[16] - Cash received from investment recovery was CNY 285,587,000.00, down 39.6% from CNY 473,000,000.00 in the previous year[27] - Total cash inflow from investment activities was CNY 297,485,123.75, a decrease of 38.4% compared to CNY 482,478,424.66 in the same period of 2020[27] - The net increase in cash and cash equivalents for Q3 2021 was CNY -480,089,700.86, slightly better than CNY -515,688,143.26 in Q3 2020[28] Assets and Liabilities - Total assets increased by 1.92% to ¥1,409,391,243.45 compared to the end of the previous year[6] - The total assets as of the end of the third quarter of 2021 amounted to ¥1,409,391,243.45, slightly up from ¥1,382,820,690.79 at the end of the previous year[18] - Total liabilities for the third quarter of 2021 were ¥54,877,055.97, a decrease from ¥59,301,062.31 in the same period of 2020, representing a reduction of approximately 7.2%[18] - The company's total non-current assets reached ¥386,810,615.08, an increase from ¥259,680,565.72 in the previous year, indicating a growth of approximately 48.9%[18] Shareholder Information - The company reported a total of 53,100,000 restricted shares held by domestic state-owned legal entities, with no shares under lock-up conditions[13] - The top ten shareholders include Beiyou Limited with 14,490,000 shares and China Merchants Bank with 4,503,851 shares, indicating significant institutional ownership[14] - The company has not disclosed any related party transactions or agreements among shareholders, ensuring transparency in ownership structure[14] Operating Costs - Total operating costs for the first three quarters of 2021 were ¥160,807,974.69, compared to ¥139,782,813.28 in 2020, indicating an increase of about 15.1%[22] - The company’s total operating expenses increased to CNY 214,146,562.70, compared to CNY 203,509,340.55 in the same period last year, reflecting a rise of 5.3%[27]